Understanding how genetic differences in antibodies affect responses to HIV
The Role of Immunoglobulin Genetic Diversity in the Development of Neutralizing Antibodies Against HIV Env Protein
This study is looking at how differences in our genes affect how well our bodies can make antibodies to fight HIV, which could help improve vaccines and treatments for people living with the virus.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Emory University NIH-funded |
| Lab location | 1 site (Atlanta, United States) |
| Project ID | NIH-11054547 on NIH RePORTER |
What this research studies
This research investigates the role of genetic diversity in immunoglobulin antibodies and how it influences the body's ability to produce neutralizing antibodies against the HIV virus. By examining variations in the immunoglobulin heavy chain gene, the study aims to uncover why some individuals develop strong antibody responses to HIV while others do not. The research will utilize both human samples and animal models to explore these genetic factors and their impact on immune responses. Patients may benefit from insights that could lead to improved vaccine strategies and treatments for HIV.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals living with HIV who have varying responses to treatment or vaccination.
Not a fit: Patients who are not infected with HIV or those who do not have a history of vaccination against HIV may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could enhance the development of more effective vaccines and therapies for HIV, potentially improving outcomes for patients living with the virus.
How similar studies have performed: Previous research has shown that understanding genetic diversity in immune responses can lead to significant advancements in vaccine development, indicating a promising avenue for this study.
Where this research is happening
Atlanta, United States
- Emory University — Atlanta, United States (Active)
Researchers
- Principal investigator: Edwards, Christopher — Emory University
- Study coordinator: Edwards, Christopher
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.